Proteomic profiling of human embryonic stem cell-derived microvesicles reveals a risk of transfer of proteins of bovine and mouse origin
| Authors | |
|---|---|
| Year of publication | 2009 |
| Type | Article in Periodical |
| Magazine / Source | Cytotherapy |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.sciencedirect.com/science/article/pii/S1465324909702804?via%3Dihub |
| Doi | http://dx.doi.org/10.1080/14653240802595531 |
| Field | Genetics and molecular biology |
| Keywords | human embryonic stem cell; hESC |
| Description | Microvesicles (MVs) serve as mediators of cell-to-cell communication. However, they may also contain immunogenic domains or infectious particles acquired from xenogenic components of the culture milieu. Therefore, MVs represent a potential risk for the clinical application of cell therapy. We tested the ability of human embryonic stem cells (hESCs) to produce MVs. We found that hESCs are potent producers of MVs and we identified 5 unique protein species that are known to be highly expressed in invasive cancers and that participate in cellular activation, metastasis, and inhibition of apoptosis. Moreover, we found that hESC-derived MVs contain immunogenic agents apolipoprotein and transferrin, as well as mouse retroviral Gag protein. These findings highlight a potential danger of the clinical use of hESCs that have been previously exposed to animal proteins or cells. |
| Related projects: |